Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients

Jung, Na Young; Yoo, Ie Ryung; Kang, Bong Joo; Kim, Sung Hun; Chae, Byung Joo; Seo, Ye Young

doi:10.1007/s12282-014-0542-2

Cited by 15 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This agrees with the study by Jung et al, [9] on the clinical significance of FDG-PET/CT in the post-operative surveillance of breast cancer patients. The calculated PET/CT sensitivity was 97.5% and the overall specificity was 98.8%.…”

Section: Discussionsupporting

confidence: 93%

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

Mohamed¹,

Ebied²,

Hussein³

2015

IJMI

View full text Add to dashboard Cite

Abstract:Objectives: The aim of this work is to compare the sensitivity and specificity of CT alone versus PET/CT in postoperative follow up of breast cancer patients. Background: Positron emission tomography (PET), using 18F-fluorodeoxyglucose (FDG) is based on the principle of increased glucose metabolism in malignant tumors and has been frequently investigated in breast cancer. Materials & Methods: Thirty female patients with breast cancer have been investigated. All patients had positive operative history. PET/CT studies were performed for post-operative follow up. The inclusion criteria in this study are histologically proved breast cancer, positive operative history and normal blood urea and creatinine levels. Exclusion criteria is pregnancy and renal impairment. Patients were divided into three groups, first group FDG PET/CT was requested for non-conclusive CT findings, second group patients referred for FDG PET/CT for elevated tumor markers, while in third group FDG PET/CT was requested for follow up after chemotherapy and/or radiotherapy. Results: A comparison of the sensitivity and specificity for CT alone versus PET/CT in each group, in the first group CT alone had sensitivity and specificity of 90% and 12.5% respectively, while PET/CT had sensitivity and specificity 100%. In the second group CT alone had sensitivity and specificity of 57% and 100% respectively, while PET/CT had sensitivity and specificity of 100%. In group three, CT alone had sensitivity and specificity of 83.3% and 84.25%, respectively and PET/CT had sensitivity of 83.3% and specificity of 100%.Conclusions: PET/CT is more sensitive and specific than CT alone for post-operative follow up of breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 93%

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

Mohamed¹,

Ebied²,

Hussein³

2015

IJMI

View full text Add to dashboard Cite

show abstract

“…The necessity of molecular-targeted therapy is based on the result of fluorescence in situ hybridization (FISH). After operation, [(18)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) can be used for detecting the recurrence and metastasis [4]. Despite advances in the diagnosis and treatment of breast cancer, some limitations remain:…”

Section: Introductionmentioning

confidence: 99%

The Clinical Application of Raman Spectroscopy for Breast Cancer Detection

Gao

Han

et al. 2017

Journal of Spectroscopy

View full text Add to dashboard Cite

Raman spectroscopy has been widely used as an important clinical tool for real-time in vivo cancer diagnosis. Raman information can be obtained from whole organisms and tissues, at the cellular level and at the biomolecular level. The aim of this paper is to review the newest developments of Raman spectroscopy in the field of breast cancer diagnosis and treatment. Raman spectroscopy can distinguish malignant tissues from noncancerous/normal tissues and can assess tumor margins or sentinel lymph nodes during an operation. At the cellular level, Raman spectra can be used to monitor the intracellular processes occurring in blood circulation. At the biomolecular level, surface-enhanced Raman spectroscopy techniques may help detect the biomarker on the tumor surface as well as evaluate the efficacy of anticancer drugs. Furthermore, Raman images reveal an inhomogeneous distribution of different compounds, especially proteins, lipids, microcalcifications, and their metabolic products, in cancerous breast tissues. Information about these compounds may further our understanding of the mechanisms of breast cancer.

show abstract

“…follow-up examination, the CA-153 level and time to detect a node after mastectomy could not directly show LR itself but only help diagnose LR, which may explain why CA-153 or the time to detect a node after mastectomy was not widely used for independent prognostic determination of recurrence and metastasis of BCa after surgery in previous studies. 17,18 Mammographic screening is not superior to a physical examination and US, and US is not superior to positron emission tomography in detecting nodal recurrences before they are palpable 19,20 ; however, positron emission tomography is not routinely performed after primary treatment. The fatality of chest wall LR is still controversial according to previous reports; however, the survival and quality of life reportedly improve because of the early detection and treatment of LR.…”

Section: Discussionmentioning

confidence: 99%

Ultrasound May Help Detect Chest Wall Recurrence After Mastectomy at an Early Stage

Wang

Liu

2020

J of Ultrasound Medicine

View full text Add to dashboard Cite

Objectives-To define ultrasound (US) features that help diagnose local recurrence (LR) and differentiate benign masses from LR chest wall masses after mastectomy in patients with breast cancer. Methods-The US and surgical records of 119 pathologically confirmed chest wall masses in 101 patients were reviewed from 4634 patients with breast cancer who underwent mastectomies. The chest wall masses were divided into 2 groups depending on their longitudinal diameter (LD; ≤10 and > 10 mm). The US features of the subgroups, depending on their nature (benign and LR), were analyzed and compared. Results-Among 119 masses, 58 (48.74%) were benign masses, and 61 (51.26%) were LR masses. For LR, the mean area under the curve AE SD, sensitivity, and specificity of US were 0.849 AE 0.033, 85.25%, and 84.48% (P < .001), respectively. Among the US characteristics, vascularity, an irregular shape, and a location in deep layers were the top 3 factors related to LR (odds ratios, 4.0, 2.6, and 2.2). To diagnose LR by US, judging the anatomic layer of the locations of masses with an LD of 10 mm or less and the presence of vascularity in masses with an LD of greater than 10 mm were helpful. Conclusions-Ultrasound is a relatively accurate and objective method to differentiate LR from a benign mass after mastectomy with follow-up. Judging the anatomic layer of the mass location with US likely increases the accuracy of LR diagnosis at an early stage.

show abstract

Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients

Abstract: FDG-PET/CT is considered as an acceptable diagnostic imaging modality for postoperative surveillance of patients with breast cancer.

Cited by 15 publications

References 18 publications

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

PET/CT Versus CT In Post-Operative Follow Up Of Breast Cancer Patients

The Clinical Application of Raman Spectroscopy for Breast Cancer Detection

Ultrasound May Help Detect Chest Wall Recurrence After Mastectomy at an Early Stage

Contact Info

Product

Resources

About